Tenaya Therapeutics Shines at AHA 2025
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a pioneering clinical-stage biotechnology firm, is set to make significant waves at the upcoming American Heart Association (AHA) Scientific Sessions in 2025. This event promises to be a major platform for innovative advancements in genetic therapies aimed at addressing heart disease.
Presentations Highlight Cutting-Edge Research
During the AHA event, Tenaya will conduct two late-breaking oral presentations that focus on its promising gene therapy products, particularly TN-201. This investigational therapy aims to tackle myosin-binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), a condition recognized for its severe impact on heart function due to the deficiency of MyBP-C.
Key Insights from the MyPEAK-1 Trial
The data to be presented from the MyPEAK-1 Phase 1b/2a trial will encompass crucial interim safety and efficacy results. These findings are anticipated to showcase the potential of TN-201 in improving patient outcomes for those suffering from HCM.
Details of the Oral Presentation
Presentation Title: TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy
Session Type: Late-Breaking Science: Main Event (Oral Presentation)
Session Title: Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy
Presenter: Milind Y Desai, M.D., MBA, renowned for his work in cardiology.
Advancements in Ischemic Heart Failure Research
In addition to the TN-201 results, Tenaya will present groundbreaking findings related to cellular reprogramming treatments demonstrated in a preclinical pig model of ischemic heart failure. This innovative approach aims to regenerate cardiac cells, presenting a potential paradigm shift in the treatment of heart injuries stemming from ischemic events.
Details on the Cellular Reprogramming Presentation
Presentation Title: First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter
Session Type: Late-Breaking Basic Science (Oral Presentation)
Session Title: Next-Generation Therapies for Ischemic Heart Repair: From Cells to Imaging
Presenter: Kathy Ivey, Senior VP of Research at Tenaya Therapeutics.
Conference Call and Webcast
As part of the AHA experience, Tenaya will follow up with a conference call to discuss the TN-201 data showcased during the sessions. This call will occur on a designated date, allowing investors and analysts to delve deeper into the implications of the data presented.
About Tenaya Therapeutics
Tenaya Therapeutics remains dedicated to developing potentially curative therapies for heart diseases. The company emphasizes its commitment to utilizing advanced technologies in gene therapy, with strong candidates like TN-201 and TN-401 in its pipeline.
Frequently Asked Questions
What is the purpose of TN-201?
TN-201 is a gene replacement therapy aimed at treating hypertrophic cardiomyopathy associated with MYBPC3 deficiency.
When will the results be presented?
The presentations will occur during the AHA Scientific Sessions 2025, specifically on November 8 and 9, 2025.
How can I access the presentations?
Copies of the presentations will be available in the "Our Science" and "Investors" sections of the Tenaya Therapeutics website post-event.
Who is leading the research on TN-201?
The research is led by Dr. Milind Y Desai from the Cleveland Clinic, specializing in heart and vascular health.
What other therapies is Tenaya developing?
In addition to TN-201, Tenaya is also focused on gene therapies for other heart conditions, such as PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
